Protalix BioTherapeutics
PLX
28 hedge funds and large institutions have $11.5M invested in Protalix BioTherapeutics in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 12 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
32% more capital invested
Capital invested by funds: $8.72M → $11.5M (+$2.77M)
1.28% less ownership
Funds ownership: 1.96% → 0.68% (-1.3%)
15% less funds holding
Funds holding: 33 → 28 (-5)
25% less call options, than puts
Call options by funds: $261K | Put options by funds: $348K
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.3M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$193K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$115K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$94.4K |
| 5 |
BlackRock
New York
|
+$92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$4.3M |
| 2 |
IAM
Ion Asset Management
Herzliya,
Israel
|
-$2.21M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.78M |
| 4 |
AGC
Angelo Gordon & Co
New York
|
-$470K |
| 5 |
Citigroup
New York
|
-$260K |
PLX Hedge Fund Activity: Q1 2017 in Review
28 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2017, worth a combined $11.5M — up 32% from $8.72M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PLX and 8 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.3M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $4.3M sold.
- 28 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2017, down from 33 in Q4 2016.
- Funds reported $11.5M of Protalix BioTherapeutics stock for Q1 2017, up 32% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q1 2017 and 12 closed out, a net change of -4 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2017 was Renaissance Technologies, an estimated $1.3M added.
- The largest Protalix BioTherapeutics seller in Q1 2017 was Highbridge Capital Management, an estimated $4.3M sold.
Based on aggregated 13F filings for Q1 2017.